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Abstract: Atrial fibrillation (AF), the most common progressive tachyarrhythmia, results in structural
remodeling which impairs electrical activation of the atria, rendering them increasingly permissive to
the arrhythmia. Previously, we reported on endoplasmic reticulum stress and NAD+ depletion in AF,
suggesting a role for mitochondrial dysfunction in AF progression. Here, we examined mitochondrial
function in experimental model systems for AF (tachypaced HL-1 atrial cardiomyocytes andDrosophila
melanogaster) and validated findings in clinical AF. Tachypacing of HL-1 cardiomyocytes progressively
induces mitochondrial dysfunction, evidenced by impairment of mitochondrial Ca2+-handling,
upregulation of mitochondrial stress chaperones and a decrease in the mitochondrial membrane
potential, respiration and ATP production. Atrial biopsies from AF patients display mitochondrial
dysfunction, evidenced by aberrant ATP levels, upregulation of a mitochondrial stress chaperone
and fragmentation of the mitochondrial network. The pathophysiological role of mitochondrial
dysfunction is substantiated by the attenuation of AF remodeling by preventing an increased
mitochondrial Ca2+-influx through partial blocking or downregulation of the mitochondrial calcium
uniporter, and by SS31, a compound that improves bioenergetics in mitochondria. Together, these
results show that conservation of the mitochondrial function protects against tachypacing-induced
cardiomyocyte remodeling and identify this organelle as a potential novel therapeutic target.
Keywords: atrial fibrillation; mitochondria; MCU; Ru360; SS31
1. Introduction
Atrial fibrillation (AF) is the most common sustained clinical tachyarrhythmia and is associated with
increased mortality and morbidity [1,2]. Its incidence is age-related and expected to rise due to the aging
population. Consequently, AF will contribute significantly to the socioeconomic burden [3]. Due to its
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sustained nature, most patients progress from paroxysmal AF to persistent and longstanding persistent
AF [2]. Importantly, therapy of (longstanding) persistent AF has high failure rates, with 20–60% of
patients showing recurrence of AF within three months after ablation or electrical cardioversion [4–7].
Therapy failure in AF is related to the presence of structural remodeling of the myocardium, which,
in turn, impairs electrical activation of the atria (“electropathology”) [8]. Therefore, recent research is
increasingly directed at revealing the pathways underlying AF-induced cardiac structural remodeling
in order to develop more mechanism-directed AF therapies.
Recently, we documented that endoplasmic reticulum (ER) stress [9] and a significant reduction
in nicotinamide adenine dinucleotide (NAD+) levels [10] underlies AF-induced cardiac structural
remodeling. The ER is in close contact with mitochondria through the mitochondria-associated membranes
and it is known that via this way stress from the ER may be propagated to the mitochondria [11]. NAD+
is essential for mitochondrial redox reactions to produce ATP and thereby plays a role in the energy
metabolism, particularly in cells with high metabolic activity, such as cardiomyocytes [12]. Therefore,
in light of this information, mitochondrial function may be compromised in AF.
Although the role of mitochondria in AF pathogenesis is not clear, it is known that mitochondria
play a role in the electropathology of cardiac arrhythmias. Especially mitochondrial Ca2+ overload has
detrimental effects for mitochondrial function and partakes in the promotion of cardiac arrhythmias [13].
As AF is associated with increased cytosolic Ca2+ [14], and mitochondria buffer cytosolic Ca2+
overload [15], it is quite possible that mitochondrial function is compromised. Therefore, in this
study we examined the role of mitochondrial function in AF by measuring mitochondrial calcium
transients, ATP production, stress chaperones, membrane potential, respiration and morphology in
experimental models of AF remodeling and in AF patients. Here, we report that tachypacing of
HL-1 atrial cardiomyocytes induces mitochondrial Ca2+-handling changes, resulting in reduction in
mitochondrial membrane potential and respiration and finally disruption of the network. Furthermore,
prevention of mitochondrial Ca2+-handling changes, through partial blocking or downregulation
of the mitochondrial calcium uniporter (MCU), or improving mitochondrial bioenergetics, by the
polypeptide SS31, results in conservation of mitochondrial function and attenuation of AF remodeling.
Together, these results identify mitochondria as a novel potential therapeutic target in AF.
2. Materials and Methods
2.1. HL-1 Cardiomyocyte Cell Culture and Tachypacing
HL-1 atrial cardiomyocytes, derived from adult mouse atria, were obtained from Dr. William
Claycomb ([16], Louisiana State University, New Orleans, LA, USA) and maintained in complete
Claycomb medium (Sigma, Zwijndrecht, The Netherlands) supplemented with 10% FBS (PAA
Laboratories GmbH, Austria), 100 U/mL penicillin (Gibco, Landsmeer, The Netherlands), 100 µg/mL
streptomycin (Gibco), 4 mM l-glutamine (Gibco), 0.3 mM l-ascorbic acid (Sigma) and 100 µM
norepinephrine (Sigma). The cardiomyocytes were cultured on cell culture plastics or on glass
coverslips coated with 0.02% gelatin (Sigma) and were grown at 37 ◦C in 5% CO2.
HL-1 atrial cardiomyocytes were subjected to normal pacing (1 Hz) or tachypacing (6 Hz), 40 V
and 20 ms pulses by utilizing the C-Pace100TM-culture pacer (IonOptix Corporation, Amsterdam,
The Netherlands).
2.2. Transfection and Drug Treatments
HL-1 cardiomyocytes were transiently transfected with pDEST40-MCU-V5-HIS (#31731, Addgene,
Watertown, MA, USA) by the use of Lipofectamine 2000 (Life Technologies, Bleiswijk, The Netherlands).
MCU reduction of 40% and 20% (60% and 80% still present) was accomplished by transiently transfecting
the cardiomyocytes with different concentrations Mission esiRNA (EMU213891, Sigma) by the use
of Lipofectamine RNAiMAX (Life Technologies), 1 µg and 150 ng, respectively. Ru360 (Millipore,
Amsterdam, The Netherlands), mdivi-1 (Sigma), mitoTEMPO (Santa Cruz Biotechnology, Dallas,
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TX, USA) and SS31 (d-Arg-Dmt-Lys-Phe-NH2, prepared by Genscript, Piscataway, NJ, USA) were
dissolved according to manufacturer’s instructions. HL-1 atrial cardiomyocytes were treated with
Ru360 30 min. prior to pacing, mdivi-1 40 min. prior to pacing and mitoTEMPO and SS31 1 h prior
to pacing.
2.3. Calcium Transient Measurements
To measure mitochondrial calcium transient (CaTmito) amplitudes, HL-1 cardiomyocytes were
incubated for 30 min. with 5 µM of Rhod-2 AM ([17], Abcam, Cambridge, UK) at 37 ◦C in DMEM
(Gibco), which provides an indication of changes in mitochondrial Ca2+, followed by three times
washing with DMEM. To measure cytosolic calcium transient (CaTcyto) amplitudes, cardiomyocytes
were incubated for 30 min. with 2 µM of the Ca2+-sensitive dye Fluo-4-AM (Life Technologies) at
37 ◦C in DMEM, followed by three times washing with DMEM. Rhod-2 AM-loaded cardiomyocytes
were excited by a 600 nm laser with emission at 605 nm and Fluo-4-AM-loaded cardiomyocytes
were excited by a 488 nm laser with emission at 500-550 nm. CaTmito and CaTcyto amplitudes were
recorded with the Myocyte Calcium and Contractility System (IonOptix Corporation, city, state abbrev.
(If USA or Canada), country). The live recording of the CaT amplitudes was performed at 1 Hz
stimulation (normal pacing) at 37 ◦C. The relative value of fluorescent signals was determined utilizing
the following calculation: Fcal = F1/F0, where F1 is the fluorescent dye signal at any given time and F0
is the fluorescent signal at rest. Mean values and SEM from each experimental condition were based
on 7 consecutive CaTs in at least 25 cardiomyocytes.
2.4. Measurements of Mmitochondrial Dysfunction
ATP measurements, mitochondrial morphology analysis, mitochondrial membrane potential
analysis and mitochondrial oxygen consumption rate were performed before and after tachypacing.
2.4.1. ATP Measurements
HL-1 atrial cardiomyocytes were lysed and homogenized in 1/20 part 1.5% trichloroacetic acid
after which 1 part 1 M Tris-buffer (pH 8.0), supplemented with 1 mM sodium fluoride (NaF), was
added, according to the protocol of Promega (ENLITEN ATP assay system bioluminescence detection
for ATP measurement – instructions for the use of product FF2000). Human atrial appendage tissue
was lysed in 1 part TE-saturated phenol (10 mM Tris-HCl and 1 mM EDTA). After homogenization, 1/10
part chloroform and 1/13 part milliQ was added to 12 part of the homogenized product. The mixture
was centrifuged at 10.000× g for 5 min. at 4 ◦C. The supernatant was diluted 1000× with milliQ and
used for ATP measurement [18]. Cellular ATP levels were measured utilizing the ATP Bioluminescence
Assay Kit CLSII (Roche, Almere, The Netherlands), according to manufacturer’s instructions. In short,
homogenized samples and luciferase reagent (supplied) were added at a 1:1 ratio into a white 96-well
plate and ATP levels were measured by bioluminescence using the Mithras LB 940 Multimode
Microplate Reader (Berthold Technologies, Bad Wildbad, Germany).
2.4.2. Reactive Oxygen Species (ROS) Measurements
HL-1 atrial cardiomyocytes were lysed in radioimmunoprecipitation (RIPA) assay buffer and the
oxidation status of proteins was determined by utilizing the OxyBlot Protein Oxidation Detection
Kit (Millipore), according to manufacturer’s instructions. Lipid peroxidation was measured by MDA
expression by utilizing the OxiSelect TBARS Assay Kit (Cell Biolabs, San Diego, CA, USA), according
to manufacturer’s instructions.
2.4.3. Mitochondrial Morphology Analysis
HL-1 cardiomyocytes were incubated with 100 nM Mitotracker Deep Red (Life Technologies)
in DMEM (Gibco) for 30 min. at 37 ◦C, followed by 2× washing with DMEM and 2× washing with
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phosphate buffered saline (PBS). Cardiomyocytes were fixated with 4% formaldehyde (Klinipath,
Duiven, The Netherlands) for 15 min. at 37 ◦C, followed by washing 2× with PBS and mounting with
Vectashield (Vector Laboratories, Burlingame, CA, USA). Images were obtained by the Zeiss Axiovert
200 M MarianasTM digital imaging inverted microscope system, utilizing a 16-bit cooled charge-coupled
device camera (Cooke SensiCam SVGA, Cooke Co., Auburn Hills, MI, USA) with the CY5 filter block
and a 63×-oil objective and SlidebookTM (Intelligent Imaging Innovations Inc., Denver, CO, USA)
to control hardware and view images. Ten random fields containing at least 10 cardiomyocytes
were selected and the mitochondrial morphology per single cardiomyocyte was scored as tubular,
intermediate or fragmented by an investigator blinded for the conditions. The network was scored as
depicted and described in [19]. Briefly, the network was scored as tubular when it appeared as long,
intertwining tubules; as intermediate when the tubules were at least 30% shorter and also showed dots
(single mitochondria) in between; and as fragmented when >70% of the network were dots instead
of tubules. The amount of tubular, intermediate or fragmented cardiomyocytes were expressed as
percentage of the total cardiomyocytes to show the distribution of tubular, intermediate or fragmented
mitochondrial morphology between conditions.
2.4.4. Mitochondrial Membrane Potential Analysis
Mitochondrial membrane potential was determined by incubating the HL-1 atrial cardiomyocytes
with 100 nM TMRE (ab113852, Abcam) and 100 nM Mitotracker Deep Red (Life Technologies) in
DMEM for 20 min. at 37 ◦C, followed by 1× washing with DMEM, 1× washing with PBS and adding
complete Claycomb medium. Live images were obtained by the Zeiss Axiovert 200 M MarianasTM
digital imaging inverted microscope system, utilizing a 16-bit cooled charge-coupled device camera
(Cooke SensiCam SVGA) with CY3 and CY5 filter blocks and a 63×-oil objective and SlidebookTM
(Intelligent Imaging Innovations Inc.) to control hardware and view images. Ten random fields
containing at least 10 cardiomyocytes were recorded and mitochondrial membrane potential was
analyzed utilizing ImageJ software (v1.49, NIH, Washington, DC, USA). For analysis, the grey intensity
and cell area were measured for each separate cardiomyocyte for both TMRE and Mitotracker Deep
Red, of which background grey intensity was subtracted. TMRE values were divided by Mitotracker
Deep Red values and adjusted for cell area.
2.4.5. Measurement of Mitochondrial Oxygen Consumption Rate
Mitochondrial oxygen consumption rate (OCR) was measured with the Seahorse XFe96
Extracellular Flux Analyzer (Agilent, Santa Clara, CA, USA), utilizing the Seahorse XF Mito Stress
Test kit. After tachypacing, HL-1 cardiomyocytes were trypsinized and 3.5 × 104 cardiomyocytes
were plated per well in 0.02% gelatin-coated Seahorse XFe96-well cell culture microplates (Agilent)
and incubated at 37 ◦C and 5% CO2 for at least 20 h. One hour before the measurement, medium
was removed and replaced by DMEM containing 25 mM glucose (Sigma), 1 mM sodium pyruvate
(Lonza, Geleen, The Netherlands) and 2 mM l-glutamine (Life Technologies) and cardiomyocytes
were incubated in a non-CO2 incubator at 37 ◦C. Mitochondrial respiration was measured before
(routine) and after 1.5 µM oligomycin (leak respiration), 0.3 µM FCCP (maximal uncoupled respiration)
and 2.5 µM antimycin A and 1.25 µM rotenone (residual respiration). Experiments were performed
with 8–10 wells per condition and subsequently averaged. OCR values were adjusted for residual
respiration and cell count.
2.5. Protein Extraction and Western Blot Analysis
HL-1 atrial cardiomyocytes were lysed in RIPA assay buffer. Human atrial appendage tissue
samples were lysed in sample buffer (15% glycerol; 1% SDS; 12,5% 0.5 M Tris, pH 6.8; 2%
bromophenol-blue solution). For Western blot analysis, equal amounts of protein lysates were separated
on SDS-PAGE 4–20% mini-PROTEAN TGX or 4–20% Criterion TGX precast gels (Bio-Rad, Lunteren,
The Netherlands) and transferred to nitrocellulose membranes (Bio-Rad). Subsequently, membranes
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were incubated with primary antibodies. Signals were detected by the Amersham ECL prime Western
blotting detection reagent (GE Healthcare Life Sciences, Hoevelaken, The Netherlands) utilizing the
Amersham Imager 600 (GE Healthcare Life Sciences) and quantified by densitometry (ImageQuantTL,
GE Healthcare Life Sciences). The following primary antibodies were used: Anti-HSP60 (ADI-SPA-805,
Enzo Life Sciences, Farmingdale, NY, USA), anti-TOM20 (MCA4300Z, Bio-Rad), anti-MCU (14997S
Cell Signalling Technology, Leiden, The Netherlands), OXPHOS Antibody Cocktail (MS604, Abcam)
and anti-GAPDH (10R-G109a, Fitzgerald, Acton, MA, USA). Horseradish peroxidase-conjugated
anti-mouse or anti-rabbit (Dako, Denmark) were used as secondary antibodies, depending on the
species origin of the primary antibody.
2.6. Quantitative RT-PCR
Total RNA was isolated from HL-1 atrial cardiomyocytes using the Nucleospin RNA isolation kit
(Macherey-Nagel, Landsmeer, The Netherlands). First strand cDNA was generated by utilizing the
iScript cDNA synthesis kit (Bio-Rad) and subsequently used as a template for quantitative real-time
PCR. Relative changes in transcription level were determined utilizing the CFX384 Real-time system
C1000 Thermocycler (Bio-Rad) in combination with SYBR Green Supermix (Bio-Rad). mRNA levels
were expressed in relative units on the basis of a standard curve (serial dilutions of a calibrator cDNA
mixture) and adjusted for GAPDH levels. PCR efficiencies for all primers were between 90–110%.
Primer pairs used are the following: HSP60 fw: TGACTTTGCAACAGTCACCC and rv: GCTGTAGC
TGTTACAATGGGG, HSP10 fw: CTCCAACTTTCACACT-GACAGG and rv: GCCGAAACTGTAACC
AAAGG, MCU fw: ACTGTTCTGGGGACAGGATG and rv: ACCT-CTGCA AGGCACCTAGA and
GAPDH fw: CATCAAGAAGGTGGTGAAGC and rv: ACCACCCTGTTGCTGTAG.
Total DNA was isolated from HL-1 cardiomyocytes utilizing the Nucleospin Tissue kit
(Macherey-Nagel), according to manufacturer’s instructions. Isolated DNA was used to determine
mitochondrial DNA levels utilizing the CFX384 Real-time system C1000 Thermocycler (Bio-Rad)
in combination with SYBR Green Supermix (Bio-Rad). Mitochondrial DNA levels were adjusted
for nuclear DNA levels and analyzed using the ∆CT method [20]. Primer pairs used are the
following: COX1 fw: GCCCCAGATATAGCATTCCC and rv: GTTCATCCTGTTCCTGCTCC, 18S
rRNA: TAGAGGGACAAGTGGCGTTC and rv: CGCTGAGCCAGTCAGTGT.
2.7. Drosophila Melanogaster Heart Rate Measurements
Drosophila melanogaster heart rate measurements were performed with the w1118 strain (Genetic
Services Inc., Sudbury, MA, USA). All flies were maintained at 25 ◦C on standard medium. Five Male
and five female Drosophilas were added per tube and after 4 days adult flies were removed and drugs
(Ru360 or SS31) were added to the medium, which contained fly embryos. Controls were treated
with the vehicle demineralized water. Larvae consumed the drug or vehicle during 3 days, after
which transparent prepupae were collected and placed on a 1% agarose gel in PBS and subjected to
tachypacing (5 Hz for 20 min., 20 V and 5 ms pulses) with a C-Pace100TM culture pacer (IonOptix
Corporation). High-speed movies of spontaneous heart wall contractions in prepupae were recorded
before and after tachypacing for 3 × 10 s. at a rate of 100 frames per second by using a BlueFOX3 digital
camera on a Leica DM IL LED microscope with a 10×-objective. Heart rate was manually analyzed
with ImageJ.
2.8. Patient Material
Before surgery, patient characteristics were assessed (Table 1). Definitions for AF stages are as
follows: Paroxysmal (episodes last less than one week), persistent (episodes last longer than one
week) and longstanding persistent (episodes last more than one year). Duration of AF is based on
documented information stating the diagnosis of AF. Right and left atrial appendages were obtained
from patients with AF and patients in sinus rhythm (SR) undergoing cardiac surgery and included
in the Halt and Reverse study (MEC 2014-393) [21]. All AF and SR patients have underlying heart
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disease. After excision, the atrial appendages were immediately snap-frozen in liquid nitrogen and
stored at −80 ◦C. The study conforms to the principles of the Declaration of Helsinki. The institutional
board of the Erasmus Medical Center, Rotterdam, the Netherlands approved the study and patients
gave written informed consent.
Table 1. Demographic and clinical characteristics of patients with atrial fibrillation (AF) and patients in
sinus rhythm (SR), used for ATP measurements and Western blot analysis of atrial appendages.
SR PAF PeAF LSPeAF
N 35 14 24 14
RAA 33 13 22 12
LAA 7 4 19 8
Gender
Male (N, %) 26 (74.3) 10 (71.4) 15 (62.5) 12 (85.7)
Female (N, %) 9 (25.7) 4 (28.6) 9 (37.5) 2 (14.3)
Age (mean ± SD) 71 ± 12 70 ± 15 69 ± 9 74 ± 6
Underlying heart disease (N, %)
CAD 24 (68.6) 4 (28.6) 6 (25) 6 (42.9)
AVD 2 (5.7) 2 (14.3) 3 (12.5) 3 (21.4)
MVD 2 (5.7) 3 (21.4) 11 (45.8) 3 (21.4)
CAD + AVD 6 (17.1) 3 (21.4) 3 (12.5) 2 (14.3)
CAD + MVD 1 (2.9) 2 (14.3) 1 (4.2) 0 (0.0)
Duration of AF (mean ± SD
(months)) - 89 ± 95 61 ± 53 154 ± 90
LA dilatation (>45 mm, %) 7 (20) 3 (21.4) 13 (54.2) 11 (78.6)
LVF (N, %)
Normal 29 (82.9) 11 (78.6) 12 (50) 9 (64.3)
Mild impairment 6 (17.1) 2 (14.3) 6 (25) 4 (28.6)
Moderate impairment 0 (0.0) 1 (7.1) 5 (20.8) 1 (7.1)
Severe impairment 0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0)
Medication (N, %)
ACE 24 (68.6) 8 (57.1) 16 (66.7) 12 (85.7)
Statin 29 (82.9) 8 (57.1) 7 (29.2) 10 (71.4)
Type I AAD 0 (0.0) 2 (14.3) 0 (0.0) 0 (0.0)
Type II AAD 24 (68.6) 7 (50) 17 (70.8) 12 (85.7)
Type III AAD 0 (0.0) 5 (35.7) 3 (12.5) 1 (7.1)
Type IV AAD 0 (0.0) 0 (0.0) 1 (4.2) 1 (7.1)
Digoxin 0 (0.0) 1 (7.1) 8 (33.3) 4 (28.6)
SR: Sinus rhythm, PAF: Paroxysmal AF, PeAF: Persistent AF, LSPeAF: Longstanding persistent AF, RAA: Right atrial
appendage, LAA: Left atrial appendage, CAD: Coronary artery disease, AVD: Aortic valve disease, MVD: Mitral
valve disease, LA: Left atrium, LVF: Left ventricular function, ACE: Angiotensin-converting enzyme inhibitor, AAD:
Anti-arrhythmic drug.
2.9. Statistical Analysis
Results are expressed as mean ± SEM of 3–5 independent experiments for Western blot,
RT-PCR, ROS, ATP and OCR measurements, 3-5 independent experiments containing at least 25 or
100 cardiomyocytes per experiment for CaT and mitochondrial morphology/membrane potential
measurements, respectively and 15–20 Drosophila prepupae for heart rate analyses. Individual
group-mean differences were evaluated with a Student’s t-test and the Benjamini-Hochberg procedure
was used to adjust for multiple testing. All p-values were two-sided and a value of p ≤ 0.05 was
considered statistically significant. SPSS version 22 was used for all statistical evaluations.
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3. Results
3.1. Tachypacing Induces Mitochondrial Dysfunction and Stress
It has been recognized that AF is associated with increased cytosolic Ca2+ levels and mitochondria
are known to buffer Ca2+ [14,15]. Therefore, we examined the effect of tachypacing on mitochondrial
function, by first studying mitochondrial Ca2+-handling, by means of measuring mitochondrial calcium
transient (CaTmito) amplitudes. Initially, tachypacing increased CaTmito amplitude (Figures S1 and S2).
However, after 6 h tachypacing CaTmito were significantly reduced in amplitude compared to
normal-paced HL-1 cardiomyocytes (Figure 1A and Figure S3). These results are in concordance
with previous findings that extended periods of mitochondrial Ca2+ buffering reduce mitochondrial
Ca2+ uptake [15]. As the CaTmito amplitude is dependent on the mitochondrial membrane potential
(∆Ψmito) [15], ∆Ψmito was measured by using the fluorescent probe TMRE, which is readily sequestered
in polarized mitochondria. In line with CaTmito amplitude findings, tachypacing significantly and
progressively reduced ∆Ψmito (Figure 1B). Next, we investigated whether tachypacing induces
mitochondrial stress by measuring the levels of the mitochondrial stress-related chaperones HSP60
and HSP10, which are essential for mitochondrial function as they are important players in synthesis,
folding, transport and maintenance of mitochondrial proteins [22]. Tachypacing resulted in a significant
and progressive upregulation of HSP60 and HSP10 mRNA, suggesting the presence of mitochondrial
stress (Figure 1C,D).
To test whether tachypacing-induced CaTmito amplitude loss is associated with changes in
mitochondrial function, mitochondrial respiration was examined. Tachypacing resulted in proton leak
and reduction in ATP production (Figure 1E–G, Figures S4 and S5, [23]). Furthermore, tachypacing
initially increased the maximal respiration, which returned to control levels at longer duration of
tachypacing (Figure 1H). The decline in maximal respiration from 6 to 8 h of tachypacing is in
concordance with the decline of mitochondrial functions at 8 h of tachypacing, implying that the
increased maximal respiration at 6 h of tachypacing is a result of the cardiomyocytes trying cope with
the high activation rate. This suggests that mitochondria are able to respond to short-term tachypacing
by compensation mechanisms reflected by the increased maximal respiration and subsequent increased
CaTmito amplitude.
Next to functional changes, we studied whether tachypacing results in mitochondrial structural
changes. Hereto, we examined whether tachypacing causes alterations in mitochondrial mass.
Tachypacing did not affect protein abundance of electron transport system (ETS) complexes I, II, III
and V (Figure 1I). Similarly, no differences in the amount of mitochondrial DNA or TOM20 levels were
observed after tachypacing (Figure 1J,K), suggesting that tachypacing did not affect mitochondrial
mass. In addition, we examined the morphology of the mitochondrial network. Tachypacing induced a
time-dependent transition from a tubular to a fragmented network (Figure 1L and Figure S6), indicating
a compromised mitochondrial bioenergetic function by reducing the optimal tubular configuration of
mitochondria [24].
Together, these data demonstrate that tachypacing progressively impairs mitochondrial function
in HL-1 cardiomyocytes, by impairment of mitochondrial Ca2+-handling, increasing mitochondrial
stress, loss of ∆Ψmito, reduction in respiration and ATP production and finally fragmentation of the
mitochondrial network. Total mitochondrial complex protein content or mass remained, however, intact.
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Figure 1. Tachypacing induces mitochondrial dysfunction and stress. (A) Quantified data of 
mitochondrial calcium transient (CaTmito) amplitudes of HL-1 atrial cardiomyocytes during normal-
pacing (NP) and tachypacing (TP). (B) Mitochondrial membrane potential during NP and TP. 
Quantitative real-time PCR of mitochondrial stress markers (C) HSP60 and (D) HSP10 in response to 
NP and TP. The oxygen consumption rate showing (E) routine respiration, (F) leak respiration, (G) 
ATP production and (H) maximal respiration during NP and TP. (I) Top panel represent Western blot 
of respiratory chain complexes I, II, III and V. Lower panels reveal quantified data of the respiratory 
chain complexes normalized for GAPDH. (J) No changes in mitochondrial DNA during TP compared 
to NP. (K) Top panel represent Western blot and lower panel reveal quantified data of TOM20 
normalized for GAPDH. (L) Transition of the mitochondrial network from tubular to fragmented 
from NP to TP. *p < 0.05, ** p < 0.01, ***p < 0.001 vs. NP. 
Figure 1. Tachypacing induces mitochondrial dysfunction and stress. (A) Quantified data of mitochondrial
calcium transient (CaTmito) amplitudes of HL-1 atrial cardiomyocytes during normal-pacing (NP) and
tachypacing (TP). (B) Mitochondrial membrane potential during NP and TP. Quantitative real-time PCR of
mitochondrial stress markers (C)HSP60 and (D)HSP10 in response to NP and TP. The oxygen consumption
rate showing (E) routine respiration, (F) leak respiration, (G) ATP production and (H) maximal respiration
during NP and TP. (I) Top panel represent Western blot of respiratory chain complexes I, II, III and V.
Lower panels reveal quantified data of the respiratory chain complexes normalized for GAPDH. (J) No
c anges in mitoch ndrial DNA during TP compared to NP. (K) Top panel represent Western blot an
l wer panel reveal quantified data of TOM20 n rmalized for GAPDH. (L) Transition of the mit chondrial
etwork from tubular to fragmented from NP to TP. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NP.
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Figure 2. AF patients show mitochondrial dysfunction. (A) Cellular ATP levels in right atrial 
appendage (RAA) or left atrial appendage (LAA) of patients in sinus rhythm (SR), paroxysmal (PAF), 
persistent (PeAF) or longstanding persistent (LS) AF. (B) Top panel represent Western blot of HSP60 
and GAPDH, lower panel reveals quantified data of HSP60 normalized for GAPDH. (C) Top panel 
represent Western blot of TOM20 and GAPDH, lower panel reveals quantified data of TOM20 
normalized for GAPDH. (D) Top panel represent Western blot of respiratory chain complexes I, III, 
IV and V. Lower panels reveal quantified data of the respiratory chain complexes normalized for 
GAPDH in RAA of SR and RAA and LAA of PAF, PeAF and LS patients. (E) Electron microscopic 
images of LAA of a patient in SR (top), showing normal sarcomere structure and mitochondrial 
localization along the sarcomeres, and LAA of PeAF, showing myolysis and dispersed mitochondria. 
* p < 0.05, ** p < 0.01, ***p < 0.001 vs. SR RAA, ## p < 0.01 vs. SR LAA. 
3.2. Markers of Mitochondrial Dysfunction are Present in AF Patients 
To extend our findings to human AF, we examined mitochondrial dysfunction in left and/or 
right atrial appendages (LAA and RAA, respectively) from patients with paroxysmal (PAF), 
persistent (PeAF) and longstanding persistent (LSPeAF) AF and patients in sinus rhythm (SR). Given 
the small amount of LAA tissue samples from SR patients, we only were able to measure ATP levels. 
Cellular ATP levels were significantly increased in LAA compared to RAA. ATP levels in LAA of 
PAF and PeAF patients were significantly increased compared to LAA of SR patients, but reduced 
again in LSPeAF patients (Figure 2A). This finding suggests an initial compensatory mechanism to 
sustain the high heart rate of AF, which gets exhausted when AF persists for a longer period of time. 
Mitochondrial dysfunction is further evidenced in PeAF and LSPeAF by increased protein expression 
of HSP60 in both RAA and LAA (Figure 2B), while there is no change in expression of TOM20 (Figure 
2C) and of respiratory system complexes I, III, IV and V (Figure 2D). Due to antibody specificity, 
complexes I, III IV and V were detected in patients compared to complexes I, II, III and V in HL-1 
cardiomyocytes. In addition, upon electron microscopic examination, patients in SR have 
mitochondria localized along the entire length of intact sarcomeres, whereas PeAF shows fragmented 
and dispersed mitochondria and degraded sarcomeres (denoting myolysis, Figure 2E) [25]. 
i 2. AF patients show mitoch ndrial dysfunctio . (A) Cellular ATP levels in right atrial appendage
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blot of TOM20 and GAPDH, lower panel reveals quantified data of TOM20 ormalized for GAPDH.
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3.2. Markers of Mitochondrial Dysfunction are Present in AF Patients
To extend our findings to human AF, we examined mitochondrial dysfunction in left and/or
right atrial appendages (LAA and RAA, respectively) from patients with paroxysmal (PAF), persistent
(PeAF) and longstanding persistent (LSPeAF) AF and patients in sinus rhythm (SR). Given the small
amount of LAA tissue samples from SR patients, we only were able to measure ATP levels. Cellular
ATP levels were significantly increased in LAA compared to RAA. ATP levels in LAA of PAF and PeAF
patients were significantly increased compared to LAA of SR patients, but reduced again in LSPeAF
patients (Figure 2A). This finding suggests an initial compensatory mechanism to sustain the high
heart rate of AF, which gets exhausted when AF persists for a longer period of time. Mitochondrial
dysfunction is further evidenced in PeAF and LSPeAF by increased protein expression of HSP60 in
both RAA and LAA (Figure 2B), while there is no change in expression of TOM20 (Figure 2C) and of
respiratory system complexes I, III, IV and V (Figure 2D). Due to antibody specificity, complexes I, III
IV and V were detected in patients compared to complexes I, II, III and V in HL-1 cardiomyocytes.
In addition, upon electron microscopic examination, patients in SR have mitochondria localized along
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the entire length of intact sarcomeres, whereas PeAF shows fragmented and dispersed mitochondria
and degraded sarcomeres (denoting myolysis, Figure 2E) [25].
These results indicate that mitochondrial dysfunction, due to mitochondrial fragmentation and not
changes in mitochondrial mass, is found in an in vitro model of AF and is also present in AF patients.
3.3. Tachypacing-Induced CaTmito Loss Was Prevented by the Mitochondrial Ca2+ Uniporter Inhibitor Ru360
and Peptide SS31
As tachypacing induces impairment of mitochondrial function, we next tried to uncover
by which mechanism(s) mitochondria are impaired. To this end, the effects of four compounds,
targeting mitochondrial function via different pathways, were explored in HL-1 cardiomyocytes.
These compounds were: mdivi-1, an inhibitor of mitochondrial fragmentation [26]; mitoTEMPO,
a mitochondrial antioxidant [27]; Ru360, an inhibitor of the mitochondrial calcium uniporter (MCU) [28]
and SS31, a peptide that conserves the ETS and thereby mitochondrial bioenergetics [29]. The effects of
these compounds to counteract tachypacing-induced loss of CaTmito amplitude was examined after
6 h of tachypacing, as at this time point CaTmito amplitudes were significantly reduced (Figure 1A
and Figure S3). Both mdivi-1 and mitoTEMPO did not protect against tachypacing-induced CaTmito
amplitude reduction at any concentration applied (Figure 3A,B). Treatment with mitoTEMPO even
appears to exacerbate the phenotype of tachypacing, which may be due to such a substantial decrease
in mitochondrial ROS levels that it interferes with the physiological function of ROS. In contrast,
Ru360 significantly protected at higher concentrations against CaTmito amplitude reductions due
to tachypacing (Figure 3C). SS31, a compound used in clinical trials, such as for heart failure and
mitochondrial myopathy, showed protection against tachypacing-induced CaTmito amplitude reduction
at the highest concentration applied (Figure 3D). These results suggest that Ru360 and SS31, targeting
different mitochondrial mechanisms by MCU inhibition and mitochondrial ETS and bioenergetics
conservation, respectively, protect against loss of tachypacing-induced CaTmito amplitudes.
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3.4. Ru360 Protects against Tachypacing-Induced Mitochondrial Dysfunction
Tachypacing-induced CaTmito amplitude loss was protected by administration of 5 µM Ru360
(Figure 3C), a compound which specifically blocks Ca2+-influx through the MCU [28]. We explored
whether Ru360 treatment also ameliorated mitochondrial dysfunction and stress. Ru360 treatment
normalized cellular ATP levels (Figure 4A and Figure S7A) and protected the mitochondrial network
from tachypacing-induced fragmentation (Figure 4B, Figure S6 and S7B). However, Ru360 treatment did
not normalize transcription levels of HSP60 and HSP10 after tachypacing compared to normal-paced
cardiomyocytes (Figure 4C,D and Figure S7C,D), although the transcription levels were marginally
decreased, which may imply that mitochondrial stress is induced before the aberrant mitochondrial
Ca2+-handling.
To substantiate effectiveness of Ru360 in another model, we treated tachypaced Drosophila
melanogaster with different concentrations of Ru360. Comparable to findings in tachypaced HL-1
cardiomyocytes, Ru360 conferred protection against tachypacing-induced decrease of heart wall
contraction (heart rate) in Drosophila (Figure 4E and Figure S7E). The optimal concentration of Ru360
needed, 50 µM in Drosophila as opposed to 5 µM in HL-1 cardiomyocytes, corresponds well with prior
experiments in which concentrations needed to confer protection in Drosophila are consistently 10x
higher than in HL-1 cardiomyocytes [30].
Together, these results show that inhibition of the MCU-mediated Ca2+-influx into the mitochondria
by Ru360 protects against mitochondrial dysfunction and stress and preserves cellular function in
tachypaced cardiomyocytes.
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3.5. The MCU may Mediate Tachypacing-Induced Mitochondrial Changes
To determine whether the MCU plays an important role in tachypacing-induced mitochondrial
dysfunction, we studied the role of the MCU in more detail. Hereto, we first examined its protein level,
which was not affected by tachypacing (Figure 5A, Figure S8). Next, we manipulated MCU levels by
overexpression or knockdown. Overexpression of the MCU did not affect tachypacing-induced loss
of CaTmito amplitudes (Figure 5B, Figures S9A,B and S10A). In contrast, reducing MCU expression,
via siRNA treatment, by 20% (Figure S9C) protected against tachypacing-induced CaTmito amplitude
loss (Figure 5C, Figures S9D and S10B) and significantly increased the CaTmito amplitudes in
normal-paced cardiomyocytes (Figures S9D and S10B). Interestingly, a 40% reduction ofMCU expression
(Figure S9C) lowered CaTmito amplitudes in normal-paced cardiomyocytes and conferred no protection
in tachypaced cardiomyocytes (Figure 5C, Figure S9C,D). Our results suggest that a modest reduction in
the MCU abundance does not affect normal mitochondrial Ca2+-handling and may preserve adequate
MCU function and is, therefore, beneficial to counteract further tachypacing-induced mitochondrial
dysfunction. However, a larger reduction in MCU level seems detrimental, likely due to an impairment
of physiological mitochondrial Ca2+-influx, which is already observed under baseline conditions.
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Figure 6. Treatment with SS31 protects against mitochondrial dysfunction and stress. (A) Quantified
data showing protection of SS31 (100 nM) treatment on cellular ATP levels after normal-pacing (NP)
or tachypacing (TP). Black bars represent non-treated HL-1 cardiomyocytes, white bars represent
SS31-treated cardiomyocytes. (B) Quantified data of mitochondrial calcium transient (CaTmito)
amplitudes of HL-1 atrial cardiomyocytes after NP or TP. (C) Quantified data showing protection of
SS31 treatment on mitochondrial membrane potential during NP and TP. Quantitative real-time PCR of
mitochondrial stress markers show a slight protection of SS31 after 8h TP on (D) HSP60 and (E) HSP10
transcription levels in response to NP and TP. Black bars represent non-treated HL-1 cardiomyocytes,
white bars represent SS31-treated cardiomyocytes. The oxygen consumption rate showing (F) routine
respiration, (G) leak respiration, (H) ATP production and (I) maximal respiration during NP and TP
with and without SS31 treatment. (J) The transition of the mitochondrial network from tubular to
fragmented from NP to TP with and without SS31 treatment. (K) Quantified data showing heart
wall contraction rates (heart rate) before (SHR, spontaneous heart rate) and after tachypacing (TP and
white bars). Black bars represent non-treated Drosophila, white bars represent SS31-treated Drosophila.
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. NP or SHR, ## p < 0.01, ### p < 0.001 vs. TP (6 h), $ p < 0.05,
$$ p < 0.01, $$$ p < 0.001 vs. TP (8 h).
3.6. SS31 Protects against Tachypacing-Induced Mitochondrial Dysfunction and Stress
As Ru360 is, at the moment, only used in a pre-clinical setting, we explored whether SS31,
a compound already used in clinical trials (trade name elamipretide), also ameliorated mitochondrial
dysfunction and stress. SS31 showed a significant protection against tachypacing-induced CaTmito
amplitude reduction at the highest concentration applied (100 nM, Figure 3D). SS31 treatment
normalized cellular ATP levels (Figure 6A, Figure S11A) and partially attenuated contractile dysfunction,
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as shown by attenuation of cytosolic CaT loss after tachypacing (Figure 6B, Figures S11B and S12).
In addition, SS31 treatment attenuated tachypacing-induced loss of∆Ψmito (Figure 6C, Figure S11C) and
reduced HSP60 and HSP10 transcription levels (Figure 6D,E and Figure S11D,E). Next, we examined
whether SS31 treatment protected against the loss of mitochondrial respiration. We found that SS31
treatment significantly increases routine respiration and ATP production after 8 h tachypacing, but
did not prevent tachypacing-induced increase in leak respiration or maximal respiration (Figure 6F–I,
Figure S11F–I). Furthermore, we determined mitochondrial morphology and show that SS31 protects the
network from tachypacing-induced fragmentation (Figure 6J, Figures S6 and S11J). Finally, we explored
the effect of different concentrations (1, 5 and 10 µM) of SS31 in tachypaced Drosophila melanogaster.
In contrast to findings in tachypaced HL-1 cardiomyocytes, SS31 did not confer protection against
tachypacing-induced decrease in heart wall contractions in Drosophila (Figure 6K, Figure S11K).
Together, these results suggest that restoring mitochondrial bioenergetics and improving ETS
function by SS31 protects against mitochondrial dysfunction and stress and preserves cellular function
in tachypaced HL-1 cardiomyocytes.
4. Discussion
In the current study, we show tachypacing to progressively induce mitochondrial dysfunction,
evidenced by impairment of mitochondrial Ca2+-handling, upregulation of mitochondrial stress
chaperones, collapse of the mitochondrial membrane potential, decrease of mitochondrial respiration
and ATP levels and fragmentation of the mitochondrial network. Our data suggests that enhanced
Ca2+-influx through the MCU might be an important pathophysiological mechanism, consequently
impairing mitochondrial calcium transients. In line, mitochondrial changes, including aberrant ATP
levels and increased HSP60 expression, are present in atrial tissue of AF patients, which also show
structural remodeling (myolysis) and fragmented and dispersed mitochondrial localization. Treatment
with Ru360, an inhibitor of the MCU, or modest MCU downregulation prevented tachypacing-induced
detrimental mitochondrial changes. Furthermore, Ru360 treatment protected against contractile
dysfunction in a Drosophila melanogaster model for AF. In addition, SS31, a compound used in
clinical trials to improve ETS function and restore mitochondrial bioenergetics, protected against
tachypacing-induced detrimental mitochondrial changes in HL-1 cardiomyocytes. Together, these
results suggest that targeting mitochondria may represent a novel therapeutic strategy to counteract
AF-induced mitochondrial dysfunction.
4.1. Mitochondrial Dysfunction and Its Implication in Cardiac Disease
The findings observed in tachypaced HL-1 cardiomyocytes and Drosophila and clinical AF are in
line with other cardiac diseases. Multiple cardiac diseases, including heart failure, myocardial infarction,
ischemic heart disease, dilated cardiomyopathy, diabetic cardiomyopathy and hypertension-induced
cardiomyopathy, are associated with mitochondrial dysfunction, including mitochondrial ATP
depletion, decreased mitochondrial respiration and membrane potential and aberrant mitochondrial
morphology [31,32]. Aberrant mitochondrial morphology includes mitochondrial fragmentation and
swelling, disorganized and/or dismantled cristae, smaller mitochondria and/or reduced amount of
mitochondria [31]. Both the mitochondrial fragmentation [33] and destroyed cristae [34] result in
impairment of mitochondrial respiration, which compromise ATP production and, consequently,
cardiac contraction. Moreover, we observed reduced CaTmito, which is in concordance with previous
findings that extended periods of mitochondrial Ca2+-buffering reduce mitochondrial Ca2+ uptake,
which, in turn, negatively affects mitochondrial respiration [15]. Our findings of ATP levels in patients
suggest an initial compensatory mechanism to sustain the high heart rate of AF, which gets exhausted
when AF persists for a longer period of time. The observed differences between ATP levels in atrial
tissue of patients is likely due to heterogeneity of the patient population. At this moment, it’s the
chicken or the egg question whether AF leads to mitochondrial dysfunction or whether mitochondrial
dysfunction drives AF. However, it is believed that structural changes are already present before AF
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onset and that AF accelerates further changes [35,36]. We also show that changes are more prominent
in the LAA of AF patients, which is in line with evidence that AF affects RA and LA differently [37,38].
Although it is known that AF affects RA and LA differently, the specific mechanisms are still unknown,
but may be caused by the dilatation of the LA (which is not present in the RA).
As mitochondria comprise approximately 30% [39] of the cardiomyocyte volume and account for
90% [40] of the provided cardiac contraction energy, mitochondrial dysfunction is detrimental for the
heart. This is exemplified by the vast amount of cardiac diseases caused or worsened by mitochondrial
dysfunction. Likewise, in this study we provide evidence that mitochondrial dysfunction may also
underlie AF progression.
4.2. MCU-Mediated Mitochondrial Dysfunction and Stress in AF
Our data indicate that mitochondrial dysfunction and stress in an in vitro model of AF-related
remodeling may be caused by MCU-mediated Ca2+-influx. The MCU regulates the Ca2+-influx
through the inner mitochondrial membrane and is important for maintenance of the mitochondrial
Ca2+ homeostasis, which, in turn, is essential for cellular physiology [41]. The MCU is specifically
blocked by Ru360 [28], which protects against tachypacing-induced mitochondrial dysfunction in
the current study, possibly by decreasing mitochondrial Ca2+-influx. Such view is consistent with
observations on the key role of MCU in heart failure [42] and findings that Ru360 protects against
ischemia-reperfusion injury in in vitro [43] and in vivo [44] models. Additionally, next to its inhibition of
Ca2+-influx, Ru360 may also stimulate mitochondrial Ca2+-eﬄux, as observed for its analog ruthenium
red in rat [45].
The optimal treatment dose of Ru360 used in this study, 5 µM, does not confer a complete block
of the MCU. A complete block is accomplished by treatment with 10 µM Ru360 (as stated by the
manufacturer), a concentration that showed fewer protective effects in the current study. Similarly,
we found MCU siRNA treatment reducing MCU expression by 20% to protect cardiomyocytes against
tachypacing-induced CaTmito loss, in contrast to a 40% reduction of MCU expression, which showed
no protection and even revealed CaTmito reduction under normal-paced conditions. The latter is
in agreement with other studies [46], in which a reduction in MCU expression of 60% or more was
not protective in rat pancreatic islets. Whereas a modest reduction, as we show in the current study,
preserved adequate MCU function.
In line, experiments in MCU−/− mice support that complete or almost complete downregulation
of MCU has detrimental effects [47]. The role of MCU in normal cardiomyocyte physiology is in
accordance with a study showing increased cytosolic Ca2+ oscillations in MCU siRNA-transfected
cardiomyocytes [48]. Cytosolic Ca2+ levels influences mitochondrial morphology [49] and cytosolic
Ca2+ overload leads to mitochondrial fragmentation [44]. In turn, mitochondrial fragmentation impairs
the function of respiratory chain system [24] and, consequently, results in decreased ATP production.
Studies revealed that a reduction in ATP production increases the open state probability of sarcolemmal
KATP channels, and thereby reduces the length of the effective refractory period and action potential
duration, and promoting development of arrhythmias [50], such as AF [51]. Together, these data suggest
that a modest decrease in MCU level inhibits tachypacing-induced impairment of mitochondrial
Ca2+-handling and thereby protects against further detrimental effects on cardiomyocyte function.
4.3. Amelioration of Tachypacing-Induced Mitochondrial Dysfunction by SS31
Our data also indicate SS31 (trade name elamipretide) as a promising therapeutic compound
in AF. SS31 acts as a ROS scavenger and cardiolipin stabilizer, thereby improving ETS function and
restoring mitochondrial and cellular bioenergetics [29]. SS31 is a tetra-peptide that belongs to the
Szeto-Schiller (SS) peptides, and targets specifically the inner mitochondrial membrane (IMM), where
its maximal concentration (5000-fold) is reached within 2 min. The IMM is difficult to target by drugs
as it is highly impermeable to molecules due to its high concentration of mitochondrial proteins and
cardiolipin. Cardiolipin is an IMM-specific phospholipid that is required for optimal ETS function
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and cristae formation. Cardiolipin organizes the ETS on the cristae as supercomplexes to optimize
mitochondrial bioenergetics [52]. SS31 binds to cardiolipin, resulting in improved ETS function and
ATP synthesis [53]. In addition, SS31 scavenges ROS and inhibits mitochondrial swelling and opening
of the mitochondrial permeability transition pore, thereby preventing apoptosis [29].
We show that SS31 treatment improves several mitochondrial parameters after tachypacing,
including ATP levels, mitochondrial membrane potential and mitochondrial morphology. These
beneficial effects are also found for SS31 treatment in in vitro and in vivo neurodegenerative [54] and
other cardiac diseases, including heart failure and myocardial infarction [55,56].
SS31 treatment did not confer protection in tachypaced Drosophila, which may be due to the short
half-life of SS31 (0.8–2 h) [52,57]. In Drosophila, SS31 was added to the food for 3 days after which
prepupae were collected and subjected to tachypacing. Therefore, it is highly likely that SS31 is not
functional at the moment of heart function measurement. However, injection of SS31 directly in the
thorax of adult Drosophila was shown to confer protection against trauma-induced thoracic injury [58].
With respect to clinical dose, half-life and side effects, much may be learned from outcomes of
ongoing human trials with elamipretide in several diseases. A small phase I study with elamipretide
in heart failure patients showed promising results, as a single high infusion dose was well tolerated
in patients [59]. In addition, SS31 treatment resulted in less frequent and severe arrhythmias after
myocardial infarction [56]. Previously, we showed that ER stress-associated autophagy importantly
contributed to proteostasis derailment in AF and AF-induced structural remodeling [9]. Interestingly,
SS31 was able to attenuate increased autophagic activation in an in vivo model of heart failure [60]
and attenuated ER stress in an in vivo model of major burn injury [61]. In addition, RhoA signaling
was inhibited by SS31 treatment [60], which may be beneficial in AF as RhoA activation was found
to be detrimental by suppressing the protective heat shock response (HSR), thereby sensitizing
cardiomyocytes to proteotoxic stress [62]. Although the in vitro applied concentration of SS31 in this
study (100 nM) does not confer protection at all measured mitochondrial parameters, a combination of
SS31 with another protective experimental compound, such as GGA [63] and/or 4PBA [9] or currently
used anti-arrhythmic drugs, may increase the protective effect against AF-induced remodeling in the
clinic. Application of these combined compounds in (SS31-conjugated) nanoparticles [64] might be an
interesting option to explore in future studies.
4.4. Strengths and Limitations
One of the strengths of this study is the utilization of multiple different experimental techniques to
determine whether there is mitochondrial dysfunction in AF. All these techniques show in independent
experiments similar results, indicating that mitochondrial dysfunction underlies experimental and
clinical AF.
Although our in vitro HL-1 atrial cardiomyocyte model system, utilized in this study, has
limitations, it shares features of adult cardiomyocytes [16]. Although there may be differences, the
important advantage of utilizing the HL-1 cardiomyocyte model system is the use of genetic and
pharmacological manipulation to confirm specific molecular pathways involved in tachypacing-induced
remodeling. In addition, we have repeatedly confirmed the findings in the tachypaced HL-1 model in
the tachypaced dog model and clinical human AF [9,10,65]. The advantage of this model is that only
6-8 h of tachypacing is the most optimal condition to dissect molecular pathways involved in clinical
AF progression. In this condition, the HL-1 atrial cardiomyocyte model reproduces structural changes
as observed in paroxysmal and persistent AF patients [10,66,67].
One limitation of this study is the lack of LAA tissue from SR patients. Because of ethical issues,
LAA tissue may only be collected in case of a medical reason. Previous studies in our group ([10,23])
showed that the expression level of proteins is quite similar in LAA and RAA of SR patients, which is
also the case in the ATP assay in this study. Therefore, we are confident that protein expression level in
LAA of AF patients is indeed increased.
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Another issue with the included patients is the insuperable differences in medication regime.
Medication may influence mitochondrial function. Since the drug usage within the various stages of
AF is comparable, one may argue that the effect on mitochondrial function within the AF groups is due
to the arrhythmia and not to variations in medication.
The use of Rhod-2 AM as a mitochondrial Ca2+-indicator is controversial. However, when HL-1
cardiomyocytes, simultaneously treated with Rhod-2 AM and Fluo-4 AM, were subjected to short-term
tachypacing, a different effect on the CaT amplitudes between both dyes were observed, indicating
that calcium fluxes in different cellular compartments were measured, i.e., mitochondria for Rhod-2
AM and cytosol for Fluo-4 AM. Moreover, several other studies successfully utilized Rhod-2 AM as a
mitochondrial Ca2+-indicator [68,69]. Therefore, we are confident that the measured mitochondrial
CaT with Rhod-2 AM reflect the actual calcium fluxes within the mitochondria.
The MCU OE plasmid showed an increased MCU protein expression, however, we did not
determine the localization to the mitochondria. Nevertheless, functionally we show that MCU OE and
downregulating of MCU, by siRNA, has a detrimental and beneficial effect, respectively on CaTmito,
indicating that MCU modulated mitochondrial calcium.
5. Conclusions
The current study implicates that mitochondrial dysfunction is involved in AF promotion and
that targeting of mitochondria may represent a novel therapeutic strategy to counteract AF-induced
mitochondrial dysfunction.
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